Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard bought 43,618 shares of Argos Therapeutics stock in a transaction dated Thursday, September 29th. The stock was acquired at an average price of $4.56 per share, for a total transaction of $198,898.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.97 on Friday. Argos Therapeutics Inc. has a one year low of $1.61 and a one year high of $13.97. The company’s market capitalization is $204.74 million. The company’s 50-day moving average is $4.78 and its 200 day moving average is $5.93.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.05. On average, equities analysts anticipate that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current year.
Several institutional investors have recently bought and sold shares of ARGS. California State Teachers Retirement System bought a new position in Argos Therapeutics during the second quarter worth $137,000. Schwab Charles Investment Management Inc. bought a new position in Argos Therapeutics during the second quarter worth $137,000. KCG Holdings Inc. bought a new position in Argos Therapeutics during the second quarter worth $163,000. BlackRock Investment Management LLC boosted its position in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the period. Finally, Geode Capital Management LLC boosted its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the period. 11.05% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Monday, August 15th. FBR & Co reduced their target price on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 11th. Piper Jaffray Cos. restated an “overweight” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Monday, June 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Argos Therapeutics in a report on Friday, June 17th. Eight investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $11.50.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.